Code | CSB-MA177758 |
Size | US$166 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
IHC | 1:20-1:200 |
Through the use of immunization and hybridoma technology, an F13A1 monoclonal antibody was developed. To produce the antibody, B cells were extracted from the spleen of mice that were previously immunized with a synthesized peptide derived from human F13A1 and then fused with myeloma cells to create hybridomas. After screening and selecting, the F13A1-generating hybridomas were cultured in the mouse abdominal cavity. The F13A1 monoclonal antibody was purified from mouse ascites using affinity chromatography with specific immunogens. This purified F13A1 monoclonal antibody has been validated for use in ELISA and IHC applications.
F13A1 plays a key role in the blood clotting process. It acts as a transglutaminase enzyme, which means it crosslinks fibrin (the main protein in blood clots) to make it stronger and more stable. F13A1 is synthesized and secreted by platelets and monocytes/macrophages, and it is activated by thrombin to carry out its function in the final stages of clot formation. In addition to its role in blood clotting, F13A1 has been implicated in other biological processes, including wound healing and bone remodeling.
There are currently no reviews for this product.